Mark J. Gergen
2017 - Halozyme Therapeutics
In 2017, Mark J. Gergen earned a total compensation of $1.6M as Former Senior Vice President and Chief Operating Officer at Halozyme Therapeutics, a 28% decrease compared to previous year.
Compensation breakdown
| Option Awards | $550,000 |
|---|---|
| Salary | $365,603 |
| Stock Awards | $550,006 |
| Other | $146,951 |
| Total | $1,612,560 |
Gergen received $550K in stock awards, accounting for 34% of the total pay in 2017.
Gergen also received $550K in option awards, $365.6K in salary and $147K in other compensation.
Rankings
In 2017, Mark J. Gergen's compensation ranked 6,607th out of 14,666 executives tracked by ExecPay. In other words, Gergen earned more than 55.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,607 out of 14,666 | 55th |
Division Manufacturing | 2,443 out of 5,768 | 58th |
Major group Chemicals And Allied Products | 784 out of 2,074 | 62nd |
Industry group Drugs | 605 out of 1,730 | 65th |
Industry Biological Products, Except Diagnostic Substances | 110 out of 316 | 65th |
Source: SEC filing on March 22, 2018.
Gergen's colleagues
We found four more compensation records of executives who worked with Mark J. Gergen at Halozyme Therapeutics in 2017.